Background There is an increasing literature demonstrating the benefits of prehospital and
early in‐hospital transfusions. RhD‐positive products might only be available during these …

BACKGROUND Traumatic hemorrhage is the leading cause of preventable death. Early in
the resuscitation, only RhD-positive red blood cells are likely to be available, which poses a …

Background RhD‐negative blood products are in chronic short supply leading to renewed
interest in utilizing RhD‐positive blood products for emergency transfusions. This study …

Background The use of blood products early in the resuscitation of bleeding trauma patients
is widely accepted, but made difficult by limited supplies of D− red blood cell (RBC) …

Background A risk assessment model for predicting the risk of haemolytic disease of the
fetus and newborn (HDFN) in future pregnancies following the transfusion of Rh (D)‐positive …

Background and Objectives D‐negative red cells are transfused to D‐negative females of
childbearing potential (CBP) to prevent haemolytic disease of the foetus and newborn …

The use of blood products to resuscitate injured and massively bleeding patients in the
prehospital and early in-hospital phase of the resuscitation is increasing. Using group O red …

Background: Whole blood transfusion is associated with benefits including improved
survival, coagulopathy, and decreased transfusion requirements. The majority of whole …

Background After the transfusion of RhD-positive red blood cell (RBC)-containing products
to an RhD-negative woman of childbearing potential (WCP) during trauma resuscitation …

BACKGROUND Most low‐risk obstetric patients do not have crossmatched blood available
to treat unexpected postpartum hemorrhage. An emergency‐release blood transfusion …